• Safety evaluation of clinically significant adverse events [ Time Frame: Monitor for safety until Week 68 or EOS ]
  To evaluate the proportion of subjects with treatment-emergent medically-attended adverse events (MAEs), serious adverse events (SAEs), immune-mediated adverse events of special interest (AESIs), acute myocardial infarctions (AMIs), and deaths
• Evaluation of seroprotection rate (SPR) [ Time Frame: Week 20 ]
  To evaluate the immunogenicity induced by HEPLISAV-B® when administered according to the proposed dosing schedule, as measured by the SPR, defined as antibody to hepatitis B surface antigen (anti-HBs) ≥10 mIU/mL

• Safety evaluation [ Time Frame: Monitor for safety until Week 68 or EOS ]
  To evaluate the safety of HEPLISAV-B® in participants with ESRD on hemodialysis with respect to clinically significant adverse events
• Evaluation of seroprotection rate (SPR) [ Time Frame: Week 20 ]
  To evaluate the immunogenicity induced by HEPLISAV-B® when administered according to the proposed dosing schedule, as measured by the SPR, defined as antibody to hepatitis B surface antigen (anti-HBs) ≥10 mIU/mL

• Evaluation of immunogenicity [ Time Frame: Weeks 4, 8, 16, 20 ]
  To evaluate the immunogenicity induced by HEPLISAV-B® as measured by the percentage of subjects with anti-HBs concentration ≥100 mIU/mL
• Evaluation of immunogenicity [ Time Frame: Weeks 4, 8, 16, 20 ]
  To evaluate the immunogenicity induced by HEPLISAV-B® as measured by the serum anti-HBs geometric mean concentration (GMC)
• Evaluation of immunogenicity [ Time Frame: Weeks 4, 8, 16, 20 ]
  To evaluate the immunogenicity induced by HEPLISAV-B® at each study visit through 20 weeks after the first dose of study vaccine as measured by the SPR

Inclusion Criteria:

• Male and female subjects at least 18 years of age
• Laboratory confirmed negative serology result to hepatitis B virus (HBV) surface antigen (HBsAg), antibody to hepatitis B surface antigen (anti-HBs), and antibody to hepatitis B core antigen (anti-HBc) prior to first study injection
• Must be clinically stable and in the opinion of the investigator able to comply with all study procedures
• Must be able and willing to provide informed consent
• Receiving hemodialysis or will initiate hemodialysis within 4 weeks of first study injection
• Women of childbearing potential (WOCBP) must consistently use an acceptable method of contraception or confirm in writing she will abstain from sexual activity from the Screening visit through 4 weeks after the last dose of study injection. Acceptable birth control methods include but are not limited to oral contraceptive medication, an intrauterine device (IUD), an injectable contraceptive (such as medroxyprogesterone acetate or Depo-Provera®), a birth control patch, or a barrier method (such as condom or diaphragm with spermicide).

Exclusion Criteria:

• Previous receipt of any hepatitis B vaccine
• History of human immunodeficiency virus (HIV) or hepatitis C virus (HCV) infection or antibody to HIV or HCV
• History of sensitivity to any component of study vaccine
• Substance or alcohol abuse that in the opinion of the investigator would interfere with compliance or with interpretation of the study results
• Recent or ongoing history of febrile illness (within 7 days of the first study injection)

• Has received any of the following prior to the first study injection:

  • Within 14 days:

    a. Any inactivated vaccine

  • Within 28 days:

    1. Systemic corticosteroids (more than 3 consecutive days) or other immunomodulatory or immune suppressive medication with the exception of inhaled steroids
    2. Any live virus vaccine
    3. Granulocyte colony-stimulating factor (G-CSF) or granulocyte-macrophage colony-stimulating factor (GM-CSF)
    4. Any other investigational medicinal agent

  • Within 90 days:

    1. Blood products or immunoglobulin
• If female and pregnant, nursing, or planning to become pregnant during the study
• Undergoing chemotherapy or expected to receive chemotherapy during the study period

• Has a medical condition considered by the investigator likely to interfere with the subject's compliance or the interpretation of study assessments, including the following laboratory abnormalities which the investigator may consider if severe:

  • Anemia
  • Thrombocytopenia
  • Leukocytosis
  • Neutropenia
  • Metabolic acidosis
  • Increased alanine aminotransferase (ALT) or aspartate aminotransferase (AST)
  • Hyperkalemia
  • Hypokalemia
• Is scheduled to undergo a kidney transplant within 6 months of the first study injection